Co-Diagnostics, Inc. filed a Form S-3 registration statement with the SEC on November 4, 2026, covering the resale of up to 39,594,495 shares of common stock by selling stockholder J.J. Astor & Co. in connection with a convertible loan arrangement entered into on October 9, 2026.
Key Highlights
- Shares registered: Up to 39,594,495 shares of common stock, representing 200% of the maximum shares issuable under the Notes, Commitment Shares, and any applicable make-whole shares.
- Selling stockholder: J.J. Astor & Co., a Utah corporation, is the sole selling stockholder; the company will not receive any proceeds from the resale.
- Loan agreement: On October 9, 2026, the company entered into a Loan Agreement with Astor providing aggregate principal funding of up to $3.1 million.
- Initial Note: At initial closing, Astor funded $2.1 million and the company issued a senior secured convertible installment promissory note with an original principal amount of $2.835 million.
- Additional Note: The company may borrow an additional $1.0 million and issue an additional note with an original principal amount of $1.35 million, subject to terms and conditions of the Loan Agreement.
- Commitment Shares: The company issued 600,000 shares of common stock to Astor as commitment shares in connection with the transaction.
- Stock price at filing: The last reported sale price of common stock on November 3, 2026, was $0.38 per share on the Nasdaq Capital Market.
Co-Diagnostics Registers Resale Shares Tied to October 2026 Convertible Note Transaction
According to the filing, Co-Diagnostics, Inc. (NASDAQ:CODX) submitted a Form S-3 registration statement on November 4, 2026, to register up to 39,594,495 shares of its common stock, par value $0.001 per share, for resale by J.J. Astor & Co. The shares arise from a Loan Agreement executed on October 9, 2026, under which Astor agreed to provide loans to the company in an aggregate principal funding amount of up to $3.1 million.
The filing disclosed that at the initial closing, Astor funded $2.1 million and the company issued an Initial Note with an original principal amount of $2.835 million. The company may also borrow an additional $1.0 million under an Additional Note carrying an original principal amount of $1.35 million, subject to the terms and conditions of the Loan Agreement. In addition to the Notes, the company issued 600,000 shares to Astor as commitment shares. The prospectus states that the 39,594,495 shares being registered represent 200% of the sum of the maximum shares issuable upon conversion of the Notes, the Commitment Shares, and any applicable make-whole shares.
The filing stated that the company will not receive any proceeds from the resale of shares by the selling stockholder. The Selling Stockholder will receive all net proceeds from any such sales. The company is bearing the cost of registering the shares as well as various related expenses, while Astor is responsible for any broker or similar commissions on sales. Sales may occur at fixed prices, at prevailing market prices, at prices related to prevailing market prices, or at negotiated prices. The company noted it is a "smaller reporting company" as defined under federal securities laws.
What Was Disclosed
Co-Diagnostics filed an S-3 registration statement on November 4, 2026, registering up to 39,594,495 shares for resale by J.J. Astor & Co., connected to a convertible loan arrangement of up to $3.1 million in aggregate principal funding entered into on October 9, 2026.




Please wait processing your request...